Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BB-1701

Generic Name: BB-1701

Drug Type: Biotech

Overview

BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

Background

BB-1701 is a humanized IgG1 kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin developed by Bliss Biopharmaceutical.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Phase 2

Active, not recruiting

Posted: 2024/01/03

Sponsor:Eisai Inc.

ID:NCT06188559

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Phase 1

Active, not recruiting

Posted: 2020/02/05

Sponsor:Bliss Biopharmaceuti...

ID:NCT04257110

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

ANGLE's Parsortix System Shows Promise in Real-Time HER2 Status Monitoring for Breast Cancer Patients

2 months ago

ANGLE plc has successfully completed development of two assays for AstraZeneca: an Androgen Receptor assay for prostate cancer and a DNA damage response micronuclei assay, positioning the company for large-scale clinical trials.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy